ProfileGDS5678 / 1450261_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% 3% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.000113
GSM967853U87-EV human glioblastoma xenograft - Control 21.987043
GSM967854U87-EV human glioblastoma xenograft - Control 31.988593
GSM967855U87-EV human glioblastoma xenograft - Control 41.947253
GSM967856U87-EV human glioblastoma xenograft - Control 51.943123
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.0223
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 21.99283
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 31.969073
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 41.971443
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 11.978573
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 21.97553
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 31.963013
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 41.981473
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 51.978893